{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T19:38:42Z","timestamp":1793389122652,"version":"4.5.0"},"reference-count":54,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004951","name":"Atat\u00fcrk \u00dcniversitesi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004951","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Life Sciences"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.lfs.2022.121093","type":"journal-article","created":{"date-parts":[[2022,10,18]],"date-time":"2022-10-18T02:30:55Z","timestamp":1666060255000},"page":"121093","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"special_numbering":"C","title":["Inhibition of thioredoxin reductase 1 by vulpinic acid suppresses the proliferation and migration of human breast carcinoma"],"prefix":"10.1016","volume":"310","author":[{"given":"\u015eeyda Nur","family":"Kal\u0131n","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmet","family":"Altay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harun","family":"Budak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lfs.2022.121093_bb0005","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2018.00227","article-title":"Recent advances in the treatment of breast cancer","volume":"8","author":"Tong","year":"2018","journal-title":"Front. Oncol."},{"key":"10.1016\/j.lfs.2022.121093_bb0010","doi-asserted-by":"crossref","first-page":"3786","DOI":"10.1172\/JCI60534","article-title":"Heterogeneity in breast cancer","volume":"121","author":"Polyak","year":"2011","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.lfs.2022.121093_bb0015","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2014\/469251","article-title":"Breast cancer survival defined by the ER\/PR\/HER2 subtypes and a surrogate classification according to tumor grade and immunohistochemical biomarkers","volume":"2014","author":"Parise","year":"2014","journal-title":"J. Cancer Epidemiol."},{"key":"10.1016\/j.lfs.2022.121093_bb0020","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.3390\/cancers11081191","article-title":"Reactive oxygen species in the tumor microenvironment: an overview","volume":"11","author":"Weinberg","year":"2019","journal-title":"Cancers (Basel)."},{"key":"10.1016\/j.lfs.2022.121093_bb0025","doi-asserted-by":"crossref","DOI":"10.1177\/1177271918755391","article-title":"Reactive oxygen species: a key constituent in cancer survival","volume":"13","author":"Kumari","year":"2018","journal-title":"Biomarker insights."},{"key":"10.1016\/j.lfs.2022.121093_bb0030","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.bcp.2017.07.020","article-title":"Activation of ALDH1A1 in MDA-MB-468 breast cancer cells that over-express CYP2J2 protects against paclitaxel-dependent cell death mediated by reactive oxygen species","volume":"143","author":"Allison","year":"2017","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.lfs.2022.121093_bb0035","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.1158\/1535-7163.MCT-12-0093","article-title":"Sorafenib-induced hepatocellular carcinoma cell death depends on reactive oxygen species production in vitro and in vivo","volume":"11","author":"Coriat","year":"2012","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.lfs.2022.121093_bb0040","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1089\/ars.2011.4322","article-title":"Thioredoxin and thioredoxin target proteins: from molecular mechanisms to functional significance","volume":"18","author":"Lee","year":"2013","journal-title":"Antioxid. Redox Signal."},{"key":"10.1016\/j.lfs.2022.121093_bb0045","series-title":"Targeting the Selenoprotein Thioredoxin Reductase 1 for Anticancer Therapy","first-page":"139","author":"Arn\u00e9r","year":"2017"},{"key":"10.1016\/j.lfs.2022.121093_bb0050","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1146\/annurev-pharmtox-052220-102509","article-title":"Thioredoxin reductase inhibition for cancer therapy","volume":"62","author":"Gencheva","year":"2022","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.lfs.2022.121093_bb0055","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1021\/np100550t","article-title":"Modern natural products drug discovery and its relevance to biodiversity conservation","volume":"74","author":"Kingston","year":"2011","journal-title":"J. Nat. Prod."},{"key":"10.1016\/j.lfs.2022.121093_bb0060","doi-asserted-by":"crossref","first-page":"4769","DOI":"10.1016\/j.ejmech.2011.07.057","article-title":"Natural products: an evolving role in future drug discovery","volume":"46","author":"Mishra","year":"2011","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.lfs.2022.121093_bb0065","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1515\/znc-2014-4178","article-title":"Anti-angiogenic and antiproliferative properties of the lichen substances (-)-usnic acid and vulpinic acid","volume":"70","author":"Koparal","year":"2015","journal-title":"Zeitschrift F\u00fcr Naturforsch. C."},{"key":"10.1016\/j.lfs.2022.121093_bb0070","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1007\/s00300-009-0602-9","article-title":"Lecanoric acid, a secondary lichen substance with antioxidant properties from Umbilicaria Antarctica in maritime Antarctica (King George Island)","volume":"32","author":"Luo","year":"2009","journal-title":"Polar Biol."},{"key":"10.1016\/j.lfs.2022.121093_bb0075","doi-asserted-by":"crossref","first-page":"14496","DOI":"10.3390\/molecules190914496","article-title":"Antioxidant activity and mechanisms of action of natural compounds isolated from lichens: a systematic review","volume":"19","author":"White","year":"2014","journal-title":"Molecules"},{"key":"10.1016\/j.lfs.2022.121093_bb0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.cbi.2022.109984","article-title":"Diffractaic acid, a novel TrxR1 inhibitor, induces cytotoxicity, apoptosis, and antimigration in human breast cancer cells","volume":"361","author":"Kal\u0131n","year":"2022","journal-title":"Chem. Biol. Interact."},{"key":"10.1016\/j.lfs.2022.121093_bb0085","first-page":"1599","article-title":"Lichen acids may be used as a potential drug for cancer therapy; by inhibiting mitochondrial thioredoxin reductase purified from rat lung, anticancer. Agents","volume":"18","author":"Ozgencli","year":"2019","journal-title":"Med. Chem."},{"key":"10.1016\/j.lfs.2022.121093_bb0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2022.112734","article-title":"Lecanoric acid mediates anti-proliferative effects by an M phase arrest in colon cancer cells","volume":"148","author":"Roser","year":"2022","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.lfs.2022.121093_bb0095","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s40659-021-00360-4","article-title":"The role of vulpinic acid as a natural compound in the regulation of breast cancer-associated miRNAs","volume":"54","author":"Cansaran-Duman","year":"2021","journal-title":"Biol. Res."},{"key":"10.1016\/j.lfs.2022.121093_bb0100","doi-asserted-by":"crossref","first-page":"35297","DOI":"10.1039\/C7RA05059C","article-title":"Vulpinic acid contributes to the cytotoxicity of pulveroboletus ravenelii to human cancer cells by inducing apoptosis","volume":"7","author":"Kim","year":"2017","journal-title":"RSC Adv."},{"key":"10.1016\/j.lfs.2022.121093_bb0105","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1080\/13813455.2019.1662454","article-title":"Silver(I) complexes containing diclofenac and niflumic acid induce apoptosis in human-derived cancer cell lines","volume":"128","author":"Altay","year":"2022","journal-title":"Arch. Physiol. Biochem."},{"key":"10.1016\/j.lfs.2022.121093_bb0110","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1007\/s12013-021-00984-z","article-title":"In vitro anticancer activity of novel Co(II) and Ni(II) complexes of non-steroidal anti-inflammatory drug niflumic acid against human breast adenocarcinoma MCF-7 cells","volume":"79","author":"Caglar","year":"2021","journal-title":"Cell Biochem. Biophys."},{"key":"10.1016\/j.lfs.2022.121093_bb0115","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1006\/meth.2001.1262","article-title":"Analysis of relative gene expression data using real-time quantitative PCR and the 2\u2212\u0394\u0394CT method","volume":"25","author":"Livak","year":"2001","journal-title":"Methods"},{"key":"10.1016\/j.lfs.2022.121093_bb0120","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1002\/cbin.11227","article-title":"ING5 inhibits cancer aggressiveness by inhibiting akt and activating p53 in prostate cancer","volume":"44","author":"Barlak","year":"2020","journal-title":"Cell Biol. Int."},{"key":"10.1016\/j.lfs.2022.121093_bb0125","doi-asserted-by":"crossref","DOI":"10.1007\/s10534-022-00435-z","article-title":"Tip60\/Kat5 may be a novel candidate histone acetyltransferase for the regulation of liver iron localization via acetylation","author":"Baltac\u0131","year":"2022","journal-title":"BioMetals."},{"key":"10.1016\/j.lfs.2022.121093_bb0130","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1006\/abio.1997.2373","article-title":"Determination of thioredoxin reductase activity in rat liver supernatant","volume":"253","author":"Hill","year":"1997","journal-title":"Anal. Biochem."},{"key":"10.1016\/j.lfs.2022.121093_bb0135","doi-asserted-by":"crossref","DOI":"10.1002\/jbt.22704","article-title":"Coaction of hepatic thioredoxin and glutathione systems in iron overload-induced oxidative stress","volume":"35","author":"S\u00f6nmez Ayd\u0131n","year":"2021","journal-title":"J. Biochem. Mol. Toxicol."},{"key":"10.1016\/j.lfs.2022.121093_bb0140","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.3389\/fphar.2019.01180","article-title":"Piperlongumine, a novel TrxR1 inhibitor, induces apoptosis in hepatocellular carcinoma cells by ROS-mediated ER stress","volume":"10","author":"Zhang","year":"2019","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.lfs.2022.121093_bb0145","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.redox.2015.12.004","article-title":"The thioredoxin system in breast cancer cell invasion and migration","volume":"8","author":"Bhatia","year":"2016","journal-title":"Redox Biol."},{"key":"10.1016\/j.lfs.2022.121093_bb0150","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/S0002-9440(10)63145-8","article-title":"Up-regulation of the redox mediators thioredoxin and Apurinic\/Apyrimidinic excision (APE)\/Ref-1 in hypoxic microregions of invasive cervical carcinomas, mapped using multispectral, wide-field fluorescence image analysis","volume":"164","author":"Hedley","year":"2004","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.lfs.2022.121093_bb0155","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/S0022-2143(03)00068-4","article-title":"Increased expression of thioredoxin-1 in human colorectal cancer is associated with decreased patient survival","volume":"142","author":"Raffel","year":"2003","journal-title":"J. Lab. Clin. Med."},{"key":"10.1016\/j.lfs.2022.121093_bb0160","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.cbi.2016.12.007","article-title":"Potential anticancer activity of lichen secondary metabolite physodic acid","volume":"263","author":"Cardile","year":"2017","journal-title":"Chem. Biol. Interact."},{"key":"10.1016\/j.lfs.2022.121093_bb0165","doi-asserted-by":"crossref","DOI":"10.1016\/j.cbi.2021.109768","article-title":"Biological effects of gyrophoric acid and other lichen derived metabolites, on cell proliferation, apoptosis and cell signaling pathways","volume":"351","author":"Mohammadi","year":"2022","journal-title":"Chem. Biol. Interact."},{"key":"10.1016\/j.lfs.2022.121093_bb0170","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1177\/0960327119833745","article-title":"Vulpinic acid, a lichen metabolite, emerges as a potential drug candidate in the therapy of oxidative stress\u2013related diseases, such as atherosclerosis","volume":"38","author":"Sahin","year":"2019","journal-title":"Hum. Exp. Toxicol."},{"key":"10.1016\/j.lfs.2022.121093_bb0175","first-page":"626","article-title":"Evaluation of in vitro anticancer activity of vulpinic acid and its apoptotic potential using gene expression and protein analysis, indian J. Pharm","volume":"52","author":"K\u0131l\u0131c","year":"2018","journal-title":"Educ. Res."},{"key":"10.1016\/j.lfs.2022.121093_bb0180","first-page":"2032","article-title":"Determination of vulpinic acid effect on apoptosis and mRNA expression levels in breast cancer cell lines, anticancer. Agents","volume":"18","author":"K\u0131l\u0131\u00e7","year":"2019","journal-title":"Med. Chem."},{"key":"10.1016\/j.lfs.2022.121093_bb0185","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s13065-018-0398-1","article-title":"Design, synthesis and cytotoxic effects of curcuminoids on HeLa, K562, MCF-7 and MDA-MB-231 cancer cell lines","volume":"12","author":"Zamrus","year":"2018","journal-title":"Chem. Cent. J."},{"key":"10.1016\/j.lfs.2022.121093_bb0190","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1186\/s12885-016-2583-8","article-title":"PAC down-regulates estrogen receptor alpha and suppresses epithelial-to-mesenchymal transition in breast cancer cells","volume":"16","author":"Al-Howail","year":"2016","journal-title":"BMC Cancer"},{"key":"10.1016\/j.lfs.2022.121093_bb0195","doi-asserted-by":"crossref","first-page":"2902","DOI":"10.1038\/sj.onc.1210102","article-title":"Molecular profiling of docetaxel cytotoxicity in breast cancer cells: uncoupling of aberrant mitosis and apoptosis","volume":"26","author":"Hern\u00e1ndez-Vargas","year":"2007","journal-title":"Oncogene"},{"key":"10.1016\/j.lfs.2022.121093_bb0200","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1126\/science.278.5345.1966","article-title":"Conversion of Bcl-2 to a Bax-like Death Effector by Caspases","volume":"278","author":"Cheng","year":"1997","journal-title":"Science (80-. )"},{"key":"10.1016\/j.lfs.2022.121093_bb0205","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1080\/01926230701320337","article-title":"Apoptosis: a review of programmed cell death","volume":"35","author":"Elmore","year":"2007","journal-title":"Toxicol. Pathol."},{"key":"10.1016\/j.lfs.2022.121093_bb0210","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1093\/molehr\/4.12.1099","article-title":"The relationship between BcI2, bax and p53: consequences for cell cycle progression and cell death","volume":"4","author":"Basu","year":"1998","journal-title":"Mol. Hum. Reprod."},{"key":"10.1016\/j.lfs.2022.121093_bb0215","doi-asserted-by":"crossref","first-page":"293","DOI":"10.3109\/0284186X.2011.648340","article-title":"Multiple ways to die: non-apoptotic forms of cell death","volume":"51","author":"Tsujimoto","year":"2012","journal-title":"Acta Oncol. (Madr)"},{"key":"10.1016\/j.lfs.2022.121093_bb0220","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1242\/jcs.093575","article-title":"Die another way \u2013 non-apoptotic mechanisms of cell death","volume":"127","author":"Tait","year":"2014","journal-title":"J. Cell Sci."},{"key":"10.1016\/j.lfs.2022.121093_bb0225","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pcbi.1007493","article-title":"Contrasting the impact of cytotoxic and cytostatic drug therapies on tumour progression","volume":"15","author":"Anttila","year":"2019","journal-title":"PLoS Comput. Biol."},{"key":"10.1016\/j.lfs.2022.121093_bb0230","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1111\/j.1365-2125.2006.02713.x","article-title":"Drug development in oncology: classical cytotoxics and molecularly targeted agents","volume":"62","author":"Kummar","year":"2006","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.lfs.2022.121093_bb0235","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2016.00152","article-title":"Metabolic imaging to assess treatment response to cytotoxic and cytostatic agents","volume":"6","author":"Serkova","year":"2016","journal-title":"Front. Oncol."},{"key":"10.1016\/j.lfs.2022.121093_bb0240","doi-asserted-by":"crossref","first-page":"7280","DOI":"10.1158\/1078-0432.CCR-07-2141","article-title":"Is cell death a critical end point for anticancer therapies or is cytostasis Sufficient?","volume":"13","author":"Rixe","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.lfs.2022.121093_bb0245","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/s41392-020-0134-x","article-title":"Molecular principles of metastasis: a hallmark of cancer revisited","volume":"5","author":"Fares","year":"2020","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.lfs.2022.121093_bb0250","doi-asserted-by":"crossref","first-page":"2538","DOI":"10.1093\/carcin\/bgl111","article-title":"Thioredoxin reductase is required for the inactivation of tumor suppressor p53 and for apoptosis induced by endogenous electrophiles","volume":"27","author":"Cassidy","year":"2006","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.lfs.2022.121093_bb0255","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtemb.2020.126704","article-title":"The protective effect of the cardiac thioredoxin system on the heart in the case of iron overload in mice","volume":"64","author":"Altun","year":"2021","journal-title":"J. Trace Elem. Med. Biol."},{"key":"10.1016\/j.lfs.2022.121093_bb0260","doi-asserted-by":"crossref","first-page":"12288","DOI":"10.1073\/pnas.0701549104","article-title":"Targeting thioredoxin reductase is a basis for cancer therapy by arsenic trioxide","volume":"104","author":"Lu","year":"2007","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.lfs.2022.121093_bb0265","doi-asserted-by":"crossref","first-page":"21517","DOI":"10.1074\/jbc.M301032200","article-title":"Inhibition of proteasome activity induces concerted expression of proteasome genes and de novo formation of mammalian proteasomes","volume":"278","author":"Meiners","year":"2003","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.lfs.2022.121093_bb0270","doi-asserted-by":"crossref","first-page":"36860","DOI":"10.1038\/srep36860","article-title":"Role of thioredoxin reductase 1 in dysplastic transformation of human breast epithelial cells triggered by chronic oxidative stress","volume":"6","author":"Dong","year":"2016","journal-title":"Sci. Rep."}],"container-title":["Life Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0024320522007937?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0024320522007937?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T23:04:59Z","timestamp":1762211099000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0024320522007937"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":54,"alternative-id":["S0024320522007937"],"URL":"https:\/\/doi.org\/10.1016\/j.lfs.2022.121093","relation":{},"ISSN":["0024-3205"],"issn-type":[{"value":"0024-3205","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Inhibition of thioredoxin reductase 1 by vulpinic acid suppresses the proliferation and migration of human breast carcinoma","name":"articletitle","label":"Article Title"},{"value":"Life Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lfs.2022.121093","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"121093"}}